UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.76% | -20.98% | -42.70% | -36.43% | -32.70% |
| Total Depreciation and Amortization | 92.64% | 103.29% | 56.29% | 14.59% | -17.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | 304.88% | -- |
| Total Other Non-Cash Items | -11.97% | -27.92% | -0.15% | -11.84% | 20.67% |
| Change in Net Operating Assets | -1,018.77% | -680.82% | 230.39% | 83.42% | 995.16% |
| Cash from Operations | -54.81% | -67.87% | -43.26% | -43.55% | -30.07% |
| Capital Expenditure | 11.80% | 2.03% | -63.98% | -65.00% | -98.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 212.35% | 404.40% | 202.71% | -392.24% | -1,024.14% |
| Cash from Investing | 211.21% | 398.64% | 202.04% | -399.77% | -1,054.63% |
| Total Debt Issued | 166.85% | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -56.73% | -72.43% | -94.28% | -92.38% | -20.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -100.00% | -99.98% | -100.00% | -61.72% |
| Cash from Financing | -24.93% | -79.49% | -95.54% | -85.24% | -18.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 122.78% | -178.93% | -689.79% | -163.45% | -128.61% |